Validation of Senofilcon A With New UV / HEV Filter

NCT05099380 | Completed Results FDA Device

• 1 other identifier: CR-6470
• Study Type: interventional
• Target: 296
• Locations: 1 country
• Sites: 17

Brief Summary

This is a bilateral, dispensing, randomized, controlled, subject-masked, 2-arm parallel study to evaluate safety and efficacy

Conditions

Visual Acuity

Outcome Measures

Primary Outcomes (4)

• Overall Quality of Vision Score

  Overall quality of vision score was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. The average CLUE vision score for each lens type was reported.

  2-Week Follow-up

• Distance Monocular logMAR Visual Acuity

  Monocular visual acuity was measured on a logMAR (Logarithm of Minimal Angle of Resolution) scale and was evaluated at distance (4 meter) under high luminance high contrast lighting condition using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. Letter-by-letter results calculated the visual performance score for each chart read. LogMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20.

  2-Week Follow-up

• Proportion of Eyes With Grade 3 or Higher Slit Lamp Findings

  Slit Lamp Findings (SLF) were assessed using a biomicroscope and was graded using the FDA grading scale (Grade: 0, 1,2, 3 and 4) with grade 0 represents the absence of findings and 1 to 4 representing successively worse findings (i.e. Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe). This was performed on each subject eye at every study visit (baseline, unscheduled visits, 2-week follow-up and final evaluation). The data was then dichotomized into two groups. Those with Grade 3 or higher SLF and those with Grade 2 or lower. The proportion of eyes with Grade 3 or higher SLF was reported.

  up to 2-week follow-up

• Proportion of Eyes With Unacceptable Lens Fitting

  Contact lens fitting acceptance was assessed for each subject eye using a biomicroscope post lens insertion and the 2-week follow-up. Lens fit was a binary variable where acceptable lens fit=1 and unacceptable lens fit=0. The proportion of eyes with unacceptable lens fit was reported. Summaries presented in the Participant flow are summarized by planned arm, where as summaries for this measure are summarized by actual arm. One subject was dispensed the incorrect study lens, there for, the number of subjects that were randomized to the Control were 149 but 150 subjects were actually dispensed the control.

  Up to 2-Week Follow-up

Secondary Outcomes (4)

• Overall Comfort Scores

  2-Week Follow-up

• Overall Handling Scores

  2-Week Follow-up

• Situational Visual Performance - Indoors

  2-Week Follow-up

• Situational Visual Performance - Digital Devices

  2-Week Follow-up

Study Arms (2)

TEST lens

EXPERIMENTAL

Eligible subjects that are habitual wearers of silicone hydrogel spherical contact lenses will be randomized to the TEST Lens for the duration of the study.

Device: senofilcon A C3

CONTROL lens

ACTIVE COMPARATOR

Eligible subjects that are habitual wearers of silicone hydrogel spherical contact lenses will be randomized to the CONTROL Lens for the duration of the study.

Device: senofilcon A

Interventions

senofilcon A C3 DEVICE

TEST Lens

TEST lens

senofilcon A DEVICE

CONTROL Lens

CONTROL lens

Eligibility Criteria

• Age: 18 Years - 39 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Potential subjects must satisfy all of the following criteria to be enrolled in the study:
• Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
• Appear able and willing to adhere to the instructions set forth in this clinical protocol.
• Be between 18 and 39 (inclusive) years of age at the time of screening.
• By self-report, habitually wear spherical silicone hydrogel soft contact lenses in both eyes in a daily reusable or daily disposable wear modality (i.e. not extended wear modality). Habitual wear is defined as a minimum of 6 hours of wear per day, for a minimum of 5 days per week during the past 30 days.
• Have a habitual contact lens prescription that is current within the prior 6 months, and they must have worn that prescription for at least 2 weeks prior to entering the study.
• The subject's vertex corrected spherical equivalent distance refraction must be in the range of -1.00 through -6.00 D in both eyes.
• The subject's refractive cylinder must be 1.00 D or less.
• The subject must have best corrected visual acuity of 20/25 or better in each eye.

You may not qualify if:

• Potential subjects who meet any of the following criteria will be excluded from participating in the study:
• Be currently pregnant or lactating.
• Have any ocular or systemic allergies or diseases that may interfere with contact lens wear.
• Have any autoimmune disease or use of medication, which may interfere with contact lens wear. Habitual medications used by successful soft contact lens wearers are considered acceptable.
• Have any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy, PRK, LASIK, etc.).
• Be currently wearing lenses in a monovision, multifocal, toric, or extended wear modality.
• Have participated in a contact lens or lens care product clinical trial within 14 days prior to study enrollment
• Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of the clinical site.
• Have a history of binocular vision abnormality or strabismus.
• Have any infectious disease (e.g., hepatitis, tuberculosis) or contagious immunosuppressive diseases (e.g., HIV) by self-report. 10. Have any Grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA classification scale, any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear.
• \. Have any ocular infection. 12. Have any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
• \. Have entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, or aphakia.

Sponsors & Collaborators

• Johnson & Johnson Vision Care, Inc.: lead

Study Sites (17)

James T. Fujimoto, O.D.

Cupertino, California, 95014, United States

Location

Randall Go, OD

San Francisco, California, 94110, United States

Location

Dr. James Weber & Associates, PA

Jacksonville, Florida, 32205, United States

Location

Sabal Eye Care

Longwood, Florida, 32779, United States

Location

Flora Chen Poveda, OD, PA

Orange Park, Florida, 32073, United States

Location

Tallahassee Eye Center

Tallahassee, Florida, 32308, United States

Location

VisualEyes, Inc

Roswell, Georgia, 30076, United States

Location

Kannarr Eye Care

Pittsburg, Kansas, 66762, United States

Location

Birmingham Vision Care

Bloomfield Township, Michigan, 48301, United States

Location

Dr. Debbie H. Kim, OD

Closter, New Jersey, 07624, United States

Location

Sacco Eye Group

Vestal, New York, 13850, United States

Location

Professional Vision Care, Inc.

Westerville, Ohio, 43081, United States

Location

West Bay Eye Associates

Warwick, Rhode Island, 02888, United States

Location

Primary Eyecare Group

Brentwood, Tennessee, 37027, United States

Location

Tyler Eye Associates

Tyler, Texas, 75703, United States

Location

William J. Bogus, OD, FAAO

Salt Lake City, Utah, 84106, United States

Location

Botetourt Eyecare, LLC

Salem, Virginia, 24153, United States

Location

Results Point of Contact

• Title: John R. Buch-Sr. Principal Research Optometrist
• Organization: Johnson & Johnson Vision Care, Inc.

jbuch@its.jnj.com

1-800-843-2020

Study Officials

• Johnson & Johnson Vision Care, Inc. Clinical Trial

  Johnson & Johnson Vision Care, Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 4, 2021
• First Posted: October 29, 2021
• Study Start: October 5, 2021
• Primary Completion: November 24, 2021
• Study Completion: November 24, 2021
• Last Updated: February 6, 2023
• Results First Posted: February 6, 2023

Record last verified: 2023-01

Data Sharing

• IPD Sharing: Will share

Locations

US (17)